GGM Wealth Advisors’s AbbVie ABBV Stock Holding History

GGM Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.49M	Buy	7,753 +130	+2%	+$25.3K	0.83%	33
2024 Q4	$1.35M	Sell	7,623 -1,744	-19%	-$321K	0.71%	38
2024 Q3	$1.85M	Buy	9,367 +20	+0.2%	+$3.73K	0.8%	33
2024 Q2	$1.6M	Sell	9,347 -8	-0.1%	-$1.32K	0.73%	35
2024 Q1	$1.59M	Sell	9,355 -2,033	-18%	-$350K	0.74%	34
2023 Q4	$1.87M	Sell	11,388 -2,319	-17%	-$338K	0.77%	30
2023 Q3	$2.04M	Sell	13,707 -1,736	-11%	-$255K	0.88%	29
2023 Q2	$2.09M	Sell	15,443 -1,057	-6%	-$155K	0.85%	26
2023 Q1	$2.63M	Sell	16,500 -358	-2%	-$54.7K	1.5%	20
2022 Q4	$2.81M	Buy	16,858 +37	+0.2%	+$5.67K	1.45%	20
2022 Q3	$2.52M	Buy	16,821 +3,313	+25%	+$475K	1.36%	17
2022 Q2	$2.06M	Buy	13,508 +4	+0%	+$611	1.15%	21
2022 Q1	$2.11M	Buy	13,504 +2,054	+18%	+$298K	1.06%	19
2021 Q4	$1.57M	Buy	11,450 +550	+5%	+$65K	1.24%	18
2021 Q3	$1.18M	Hold	10,900	–	–	0.94%	25
2021 Q2	$1.28M	Hold	10,900	–	–	1.09%	24
2021 Q1	$1.22M	Buy	10,900 +422	+4%	+$45.1K	0.97%	25
2020 Q4	$1.18M	Buy	+10,478	New	+$1.01M	1.16%	21

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

GGM Wealth Advisors's ABBV Position: Q1 2025 in Review

GGM Wealth Advisors increased its AbbVie (ABBV) stake by 1.7% in Q1 2025, buying an estimated $25.3K and bringing the position to 7,753 shares worth $1.49M. The position accounts for 0.83% of the portfolio, ranked #33.

GGM Wealth Advisors first reported a position in ABBV in Q4 2020 and has held it in 18 quarters since. The position peaked at $2.81M in Q4 2022. 3,820 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

GGM Wealth Advisors held 7,753 shares of AbbVie worth $1.49M as of Q1 2025.
GGM Wealth Advisors bought 130 AbbVie shares in Q1 2025, an estimated $25.3K.
AbbVie made up 0.83% of GGM Wealth Advisors's portfolio in Q1 2025, its #33 holding.
GGM Wealth Advisors first reported a position in AbbVie in Q4 2020 and has held it in 18 quarters since.
GGM Wealth Advisors's AbbVie position peaked at $2.81M in Q4 2022.
3,820 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on GGM Wealth Advisors's 13F filing for Q1 2025, filed 1 May 2025.